324 related articles for article (PubMed ID: 25027606)
21. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
22. [New therapeutic targets in psoriatic arthritis].
Montilla Morales C; Gómez-Castro S; Sánchez M; López R; Hidalgo C; Del Pino-Montes J
Reumatol Clin; 2012 Mar; 8 Suppl 1():S15-9. PubMed ID: 22421457
[TBL] [Abstract][Full Text] [Related]
23. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
[TBL] [Abstract][Full Text] [Related]
24. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
25. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for psoriatic arthritis.
Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
[TBL] [Abstract][Full Text] [Related]
27. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Deeks ED
Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
[TBL] [Abstract][Full Text] [Related]
28. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Lespessailles E; Hall S; Hochfeld M; Hu C; Hough D; Stevens RM; Schett G
Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
[TBL] [Abstract][Full Text] [Related]
29. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
30. Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?
Elalouf O; Chandran V
Curr Rheumatol Rep; 2018 May; 20(7):36. PubMed ID: 29846825
[TBL] [Abstract][Full Text] [Related]
31. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
33. Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.
Ballegaard C; Jørgensen TS; Skougaard M; Strand V; Mease PJ; Kristensen LE; Dreyer L; Gottlieb A; de Wit M; Christensen R; Tarp S
Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1206-1217. PubMed ID: 29073353
[TBL] [Abstract][Full Text] [Related]
34. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
35. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.
Ogdie A; Liu M; Glynn M; Emeanuru K; Harrold LR; Richter S; Guerette B; Mease PJ
J Rheumatol; 2021 May; 48(5):693-697. PubMed ID: 33191289
[TBL] [Abstract][Full Text] [Related]
36. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
Abdulrahim H; Sharlala H; Adebajo AO
Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
[No Abstract] [Full Text] [Related]
38. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
Wu JJ; Pelletier C; Ung B; Tian M
Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
[No Abstract] [Full Text] [Related]
39. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
